Celyad obtains additional US patent for cancer treatment based on TCR-deficient allogeneic CAR-T cells
May 30 2017 - 1:00AM
Celyad (Euronext Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a
leader in the discovery and development of engineered cell
therapies, today announced the issuance of United States Patent No.
9,663,763 relating to Celyad’s method of treating cancer by
administering allogeneic primary human T cells that are engineered
to be T-Cell Receptor (TCR)-deficient and to express a chimeric
antigen receptor (CAR).
US Patent 9,663,763 was examined under the
Cancer Immunotherapy Pilot Program, also known as the “Patents 4
Patients” initiative, and is the third patent in Celyad’s
allogeneic intellectual property portfolio awarded by the United
States Patent and Trademark Office (USPTO). This new patent claims
specifically methods of treating cancer patients with allogeneic
TCR-deficient CAR-T immunotherapies. Earlier patents were related
to the allogeneic TCR-deficient CAR-T cells per se, and to methods
of producing them. The combination of these granted patents
strengthens Celyad’s position and further confirms its leadership
in engineered cell therapy, and in the allogeneic CAR-T space.
Allogeneic technology has the potential to
broaden the therapeutic applications of CAR T-Cell immunotherapies
as it does not depend on cells derived from the patient.
TCR-deficient CAR-T cells are aimed at avoiding or greatly reducing
adverse immune reactions (such as a graft- versus-host-disease
(GVHD) response) which would greatly benefit patients.
Dr. Christian Homsy, CEO of
Celyad: “We are pleased to have obtained this new patent.
The combination of this patent with the earlier granted US Patents
consolidates our strong IP position in the CAR-T field and
strengthens our IP portfolio covering key elements in the
allogeneic TCR-deficient CAR-T cells production value chain.”
Dr. Georges Rawadi, VP Business
Development & IP at Celyad: “Allogeneic CAR-T cells
are of increasing interest to many Pharma and BioPharma companies
involved in cell-based cancer immunotherapies. We are looking to
maximize the significant value of our allogeneic CAR-T assets
through strategic collaborations and partnerships such as the ones
we have established with ONO Pharma and Novartis.”
***END***
About CelyadCelyad is a clinical-stage
biopharmaceutical company focused on the development of specialized
cellbased therapies. The Company utilizes its expertise in cell
engineering to target cancer. Celyad’s Natural Killer Receptor
based T-Cell (NKR-T) platform has the potential to treat a broad
range of solid and hematologic tumors. Its lead oncology candidate,
the CAR-T NKR-2, has been evaluated in a single dose - escalation
Phase I clinical trial to assess the safety and feasibility of
CAR-T NKR-2 cells in patients suffering from AML or MM. This Phase
I study was successfully completed in September 2016. Celyad was
founded in 2007 and is based in Mont-Saint Guibert, Belgium, and
Boston, Massachusetts. Celyad’s ordinary shares are listed on the
Euronext Brussels and Euronext Paris exchanges, and its American
Depository Shares are listed on NASDAQ Global Market, all under the
ticker symbol CYAD.
For more information, please
contact:
For Europe: Consilium Strategic Communications
Chris Gardner and Chris Welsh
- T: +44 (0)20 3709 5700 –
celyad@consilium-comms.com |
For France: NewCapPierre
Laurent and Nicolas Mérigeau - T: +
33(0)1 44 71 94 94 - celyad@newcap.eu |
For Belgium: ComfiGunther De
Backer and Sabine Leclercq - T.: +32 (0)2
290 90 90 – celyad@comfi.be |
For the U.S.: Stern Investor RelationsWill
O’Connor and Michael Schaffzin – T.: +1
212.362.1200 – celyad@sternir.com |
To subscribe to Celyad’s newsletter,
visit www.celyad.com Follow us on LinkedIn
& Twitter @CelyadSA
Forward looking statements
In addition to historical facts or statements of current
condition, this press release contains forward looking statements,
including statements about the potential safety and feasibility of
CAR-T NKR-2 cell therapy, which reflect our current expectations
and projections about future events, and involve certain known and
unknown risks, uncertainties and assumptions that could cause
actual results or events to differ materially from those expressed
or implied by the forward-looking statements. These forward looking
statements are further qualified by important factors, which could
cause actual results to differ materially from those in the
forward-looking statements, including risks associated with
conducting clinical trials; the risk that safety, bioactivity,
feasibility and/or efficacy demonstrated in earlier clinical or
pre-clinical studies may not be replicated in subsequent studies;
risk associated with the timely submission and approval of
anticipated regulatory filings; the successful initiation and
completion of clinical trials, including Phase I clinical trial for
CAR-T NKR-2; risks associated with the satisfaction of regulatory
and other requirements; risks associated with the actions of
regulatory bodies and other governmental authorities; risks
associated with obtaining, maintaining and protecting intellectual
property, our ability to enforce our patents against infringers and
defend our patent portfolio against challenges from third parties;
risks associated with competition from others developing products
for similar uses; risks associated with our ability to manage
operating expenses; and risks associated with our ability to obtain
additional funding to support our business activities and establish
and maintain strategic business alliances and business initiatives.
A further list and description of these risks, uncertainties and
other risks can be found in the Company’s Securities and Exchange
Commission filings and reports, including in the Company’s Annual
Report on Form 20-F filed with the SEC on April 8, 2016 and future
filings and reports by the Company. Given these uncertainties, the
reader is advised not to place any undue reliance on such
forward-looking statements. These forward-looking statements speak
only as of the date of publication of this document. The Company
expressly disclaims any obligation to update any such
forward-looking statements in this document to reflect any change
in its expectations with regard thereto or any change in events,
conditions or circumstances on which any such statement is based,
unless required by law or regulation.
Celyad Oncology (EU:CYAD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Celyad Oncology (EU:CYAD)
Historical Stock Chart
From Apr 2023 to Apr 2024